In October 2015, the third batch of talent selection for the “113 Talent Program” of China Medical City in Taizhou City was completed. Dr. Tao Wenjing, the company's executive director and general manager, was selected as a high-level entrepreneurial talent.
      Dr. Tao Wenjing graduated from Nanjing Agricultural University in 1998, under the tutelage of Academician Liu Dajun, the president. After graduating from his Ph.D., she worked in the Biotechnology Research Center of the Chinese Academy of Agricultural Sciences and presided over two national "863" projects. In October 1999, she worked at the University of Guelph in Canada to conduct post-doctoral research. Five years later, she transferred to the University of Missouri Columbia. In December 2004, she joined TURNER BIOSYSTEMS, INC. as a researcher, carried out the research and development of high-throughput nucleic acid detection technology, and successfully developed ATILA high-throughput nucleic acid detection technology and obtained a US invention patent in 2007 (patent number US 8673567); After November 2006, she successively joined the world-renowned American Bio-Rad Laboratories and Merck Millipore as a senior scientist and technical leader. She has long been engaged in the research and development of clinical diagnostic reagent products and has participated Presided over the research topics of molecular labeling technology, high throughput (high throughput) detection technology, multiple immunoassay technology, participated in the development and production of a large number of multiple immunoassays and clinical diagnostic kits; also participated in a large number of microspheres and Development and verification of testing equipment; In October 2010, she joined Rules-Based Medicine in the United States as a senior researcher and director of the CLIA certification laboratory. She led the team to improve and re-verify more than 400 liquid-phase chip immunoassay reagents, and was responsible for the outsourcing projects of inspection agencies and pharmaceutical companies. She successfully developed and produced multiple tumor marker detection kit series, multiple degenerative nerve markers, multiple autoimmune marker detection kit series; from November 2011 to present, served as deputy general manager (shareholder) of United Bioresearch Inc., mainly developing Immunoassay kit. She founded BioPredia BioTech Co., Ltd. on December 26, 2014, and served as legal representative, chairman and general manager. In July 2017, she served as executive director and general manager of Nanjing BioPredia Co., Ltd. Phase chip immunomultiplex detection kit and automatic high-throughput flow fluorescence detection system. In domestic and foreign technology and product development and entrepreneurial practices, continuous innovation and self-improvement have laid a solid foundation for the development of the business.
      During the work, Dr. Tao Wenjing obtained 1 US invention patent, published more than 20 papers, of which more than 10 were retrieved by SCI, and she gave more than 10 speeches at major global academic conferences. She won the National Science and Technology Progress Award once, the Ministry of Education nominated the National Natural Science Award once, and the Ministry of Education Science and Technology Progress Award once.